Gsk Plc ADR (GSK)

$59.26 -0.26 (-0.44%)
Market Cap 121.33B
Revenue (ttm) 43.08B
Net Income (ttm) 7.54B
EPS (ttm) N/A
PE Ratio 13.46
Forward PE 12.60
Profit Margin 17.50%
Debt to Equity Ratio 1.11
Volume 6,849,300
Avg Vol 5,056,042
Day's Range N/A - N/A
Shares Out 2.04B
Stochastic %K 41%
Beta 0.46
Analysts Sell
Price Target $54.26

Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephr...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 8047 5000
Website: www.gsk.com
Address:
79 New Oxford Street, London, United Kingdom
prismmarketview
prismmarketview Feb. 23 at 7:53 PM
Bora Pharmaceuticals (OTCQX: $BORAY) is getting a visibility boost after renewing a five-year, 250 million‑dollar global manufacturing deal with GSK (NYSE: $GSK), locking in long-term CDMO revenue tied to key HIV and malaria medicines. https://prismmarketview.com/bora-pharmaceuticals-secures-250-million-manufacturing-deal-with-gsk-expanding-long-term-revenue-visibility/
0 · Reply
TinyTiger19
TinyTiger19 Feb. 17 at 6:14 PM
$GSK $RELX $LRCX $RDDT ^<>+
0 · Reply
BreakoutPika
BreakoutPika Feb. 17 at 5:51 PM
$CNH $GSK $STZ $NBIX s
0 · Reply
RunnerSignals
RunnerSignals Feb. 17 at 5:30 PM
$ZIM $KW $PGEN $GSK $CNP 5 Stocks Hitting 52-Week Highs Today. volumes are surging well above average, RSI signals extended trends. Watch for follow-through or short-term pullbacks
0 · Reply
Justrise07
Justrise07 Feb. 17 at 4:27 PM
$OCUL tecover your loss with $CAMP 3x buyout coming $GSK
0 · Reply
_EmproX
_EmproX Feb. 17 at 3:17 PM
$APH $GSK $ADBE $RDDT •1
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 17 at 2:56 PM
$GSK
0 · Reply
briefingcom
briefingcom Feb. 17 at 1:27 PM
$GSK: GlaxoSmithKline (+3.4%)receives EU approval for Exdensur in severe asthma and CRSwNP https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260217050658GSK&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
SanKish
SanKish Feb. 14 at 12:32 AM
$BMY I think this can go much higher based on price action. All tech sell off money is helping pharma too as $PFE , $GSK are doing well too. Which one amongst the 3 will you bet on more?
0 · Reply
inspector_gadget86
inspector_gadget86 Feb. 12 at 3:06 PM
$GSK Cases climb to 933 in South Carolina measles outbreak $OKYO $SPY $DJIA
0 · Reply
Latest News on GSK
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

Mon, 23 Feb 2026 13:13:00 -0500 - 8 hours ago

Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

Biodexa Licenses Phase 1-Ready Drug Candidate From Otsuka For Rare Stomach Cancer

2026-02-19T11:31:28.000Z - 4 days ago

Biodexa Licenses Phase 1-Ready Drug Candidate From Otsuka For Rare Stomach Cancer

GSK's HIV Treatment Achieves Superior Results in Phase III Trial

2026-02-18T23:26:03.000Z - 5 days ago

GSK's HIV Treatment Achieves Superior Results in Phase III Trial

Ex-Dividend Reminder: Shell, Patria Investments and Glaxosmithkline

2026-02-18T15:24:56.000Z - 5 days ago

Ex-Dividend Reminder: Shell, Patria Investments and Glaxosmithkline

GSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

Wed, 18 Feb 2026 08:00:00 -0500 - 5 days ago

GSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade)

2026-02-17T17:10:05.000Z - 6 days ago

GSK: Post-Pivot Buoyancy Set To Continue After Strong 2025 (Upgrade)

GSK's Arexvy Vaccine Shows Strong Effectiveness in Real-World Study

2026-02-17T15:01:58.000Z - 6 days ago

GSK's Arexvy Vaccine Shows Strong Effectiveness in Real-World Study

GSK says RSV shot Arexvy lowers risk of CV events, asthma, and COPD

2026-02-17T14:44:59.000Z - 6 days ago

GSK says RSV shot Arexvy lowers risk of CV events, asthma, and COPD

GSK wins approval of Exdensur in Europe for severe asthma

2026-02-17T14:07:35.000Z - 6 days ago

GSK wins approval of Exdensur in Europe for severe asthma

GSK Reports Promising Data for RSV Vaccine Effectiveness

2026-02-17T12:52:47.000Z - 6 days ago

GSK Reports Promising Data for RSV Vaccine Effectiveness

Europe Clears GSK's New Twice-Yearly Asthma Treatment

2026-02-17T11:31:31.000Z - 6 days ago

Europe Clears GSK's New Twice-Yearly Asthma Treatment

GSK Begins Fourth Tranche Of Up To GBP 0.45 Bln Share Buyback Under GBP 2 Bln Programme

2026-02-17T07:57:41.000Z - 6 days ago

GSK Begins Fourth Tranche Of Up To GBP 0.45 Bln Share Buyback Under GBP 2 Bln Programme

Noteworthy ETF Inflows: FENI, GSK, BTI, RIO

2026-02-12T15:48:22.000Z - 11 days ago

Noteworthy ETF Inflows: FENI, GSK, BTI, RIO

Is GSK PLC Gaining or Losing Market Support?

2026-02-10T17:00:47.000Z - 13 days ago

Is GSK PLC Gaining or Losing Market Support?

GSK's Arexvy Awaits Approval in China for RSV Prevention in Seniors

2026-02-10T13:04:02.000Z - 13 days ago

GSK's Arexvy Awaits Approval in China for RSV Prevention in Seniors

GSK’s Arexvy RSV vaccine accepted for regulatory review in China for seniors

2026-02-10T13:02:39.000Z - 13 days ago

GSK’s Arexvy RSV vaccine accepted for regulatory review in China for seniors

Pharma sector stocks today, Feb 10: Pfizer rally 9%, GSK Pharma up 4.12%, Divis Laboratories rises 1.47%

2026-02-10T04:43:12.000Z - 13 days ago

Pharma sector stocks today, Feb 10: Pfizer rally 9%, GSK Pharma up 4.12%, Divis Laboratories rises 1.47%

GSK (GSK) Shares Climb Amid Positive Developments and EU Approval

2026-02-06T20:57:59.000Z - 17 days ago

GSK (GSK) Shares Climb Amid Positive Developments and EU Approval

GSK shares uptick for seven consecutive sessions

2026-02-06T20:39:44.000Z - 17 days ago

GSK shares uptick for seven consecutive sessions

GSK (GSK) Gains EU Approval for Expanded Use of Nucala in COPD Treatment

2026-02-06T16:57:11.000Z - 17 days ago

GSK (GSK) Gains EU Approval for Expanded Use of Nucala in COPD Treatment

GSK wins EU nod to expand Nucala for COPD

2026-02-06T16:35:34.000Z - 17 days ago

GSK wins EU nod to expand Nucala for COPD

GSK Gains European Approval for Nucala in COPD Treatment

2026-02-06T11:53:03.000Z - 17 days ago

GSK Gains European Approval for Nucala in COPD Treatment

GSK Wins EU Approval For Nucala In COPD Treatment

2026-02-06T08:15:33.000Z - 17 days ago

GSK Wins EU Approval For Nucala In COPD Treatment

RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

Thu, 05 Feb 2026 17:30:00 -0500 - 18 days ago

RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

GSK (GSK) Q3 2025 Earnings Call Transcript

2026-02-05T16:31:52.000Z - 18 days ago

GSK (GSK) Q3 2025 Earnings Call Transcript

3 International Stocks to Buy for 2026

Thu, 05 Feb 2026 09:00:45 -0500 - 18 days ago

3 International Stocks to Buy for 2026

GSK plc 2025 Q4 - Results - Earnings Call Presentation

2026-02-05T07:50:36.000Z - 18 days ago

GSK plc 2025 Q4 - Results - Earnings Call Presentation

GSK plc (GSK) Q4 2025 Earnings Call Transcript

Wed, 04 Feb 2026 19:30:43 -0500 - 19 days ago

GSK plc (GSK) Q4 2025 Earnings Call Transcript

Glaxo's new boss goes big on science - and that should be good for Britain, says ALEX BRUMMER

2026-02-04T22:00:49.000Z - 19 days ago

Glaxo's new boss goes big on science - and that should be good for Britain, says ALEX BRUMMER

GSK's Acquisition Highlights Trend Towards Convenience-Focused Drugs

2026-02-04T19:26:47.000Z - 19 days ago

GSK's Acquisition Highlights Trend Towards Convenience-Focused Drugs

GSK Is Eyeing $55 Billion In Sales — And It Has Nothing To Do With Obesity

2026-02-04T18:35:05.000Z - 19 days ago

GSK Is Eyeing $55 Billion In Sales — And It Has Nothing To Do With Obesity

GSK, take two: the bullish tone at the top is finally more convincing | Nils Pratley

2026-02-04T18:20:17.000Z - 19 days ago

GSK, take two: the bullish tone at the top is finally more convincing | Nils Pratley

GSK PLC (GSK) Shares Up 6.49% on Feb 4

2026-02-04T17:03:49.000Z - 19 days ago

GSK PLC (GSK) Shares Up 6.49% on Feb 4

GSK PLC (GSK) Q4 2025 Earnings Call Highlights: Strong Financial Performance and Strategic ...

2026-02-04T17:01:03.000Z - 19 days ago

GSK PLC (GSK) Q4 2025 Earnings Call Highlights: Strong Financial Performance and Strategic ...

Q4 2025 GSK plc Earnings Call Transcript

2026-02-04T16:00:11.000Z - 19 days ago

Q4 2025 GSK plc Earnings Call Transcript

GSK beats expectations as specialist medicines drives profits in boost for new boss

2026-02-04T15:03:32.000Z - 19 days ago

GSK beats expectations as specialist medicines drives profits in boost for new boss

GSK Shares Jump 5.2% as New CEO Signals Faster R&D, Deal Push

2026-02-04T13:39:32.000Z - 19 days ago

GSK Shares Jump 5.2% as New CEO Signals Faster R&D, Deal Push

GSK Stock Smashes 52-Week High On Strong Quarter, Dividend Hike

2026-02-04T13:12:31.000Z - 19 days ago

GSK Stock Smashes 52-Week High On Strong Quarter, Dividend Hike

GSK Projects Moderate Growth in Turnover and Earnings by 2026

2026-02-04T11:52:42.000Z - 19 days ago

GSK Projects Moderate Growth in Turnover and Earnings by 2026

GSK Reports Strong Q4 Sales Growth Driven by Specialty Medicines

2026-02-04T11:51:27.000Z - 19 days ago

GSK Reports Strong Q4 Sales Growth Driven by Specialty Medicines

Earnings Scheduled For February 4, 2026

2026-02-04T11:11:23.000Z - 19 days ago

Earnings Scheduled For February 4, 2026

GSK Beats Estimates, Sticks With Long-Term Outlook

2026-02-04T10:45:47.000Z - 19 days ago

GSK Beats Estimates, Sticks With Long-Term Outlook

GSK (GSK) Shares Rise on Strong Q4 Earnings and Positive Outlook

2026-02-04T09:56:40.000Z - 19 days ago

GSK (GSK) Shares Rise on Strong Q4 Earnings and Positive Outlook

GSK reaffirms profit growth projections for 2026

2026-02-04T09:42:59.000Z - 19 days ago

GSK reaffirms profit growth projections for 2026

GSK posts higher profits but indicates sales growth to slow in 2026

2026-02-04T09:15:02.000Z - 19 days ago

GSK posts higher profits but indicates sales growth to slow in 2026

GSK (GSK) Declares Dividend and Announces Share Buyback Plan

2026-02-04T08:57:21.000Z - 19 days ago

GSK (GSK) Declares Dividend and Announces Share Buyback Plan

GSK declares $0.4968/ADS or 18p/share dividend

2026-02-04T08:28:30.000Z - 19 days ago

GSK declares $0.4968/ADS or 18p/share dividend

GSK (GSK) Surpasses Q4 Earnings Expectations and Reaffirms Growth Outlook

2026-02-04T07:56:49.000Z - 19 days ago

GSK (GSK) Surpasses Q4 Earnings Expectations and Reaffirms Growth Outlook

GlaxoSmithKline (GSK) Projects Slower Revenue Growth by 2026

2026-02-04T07:50:21.000Z - 19 days ago

GlaxoSmithKline (GSK) Projects Slower Revenue Growth by 2026

GSK’s Specialty Medicines Drive Solid Results

2026-02-04T07:45:00.000Z - 19 days ago

GSK’s Specialty Medicines Drive Solid Results

GSK forecasts slower sales growth in 2026

Feb 4, 2026, 2:03 AM EST - 19 days ago

GSK forecasts slower sales growth in 2026

Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path

Feb 2, 2026, 2:16 PM EST - 21 days ago

Wave Life Sciences Reclaims Rare Disease Drug From GSK, Targets Faster FDA Path

WVE

Top FTSE 100 Index shares to watch: BT Group, Vodafone, Shell, GSK

Jan 30, 2026, 3:00 AM EST - 24 days ago

Top FTSE 100 Index shares to watch: BT Group, Vodafone, Shell, GSK

SHEL VOD

GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026

Jan 21, 2026, 10:00 AM EST - 4 weeks ago

GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026

Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK

Jan 20, 2026, 2:13 PM EST - 4 weeks ago

Forbion Announces Second Exit from Forbion Growth Fund III Following $2.2 Billion Acquisition of RAPT Therapeutics by GSK

RAPT

GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million

Jan 20, 2026, 9:00 AM EST - 4 weeks ago

GSK Announces Recipients of Linked by Lupus: Optimal Care Initiative Grants Nearing $1 Million

GSK to buy food allergy drug maker RAPT in $2.2bn deal

Jan 20, 2026, 7:20 AM EST - 4 weeks ago

GSK to buy food allergy drug maker RAPT in $2.2bn deal

RAPT

GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug

Jan 20, 2026, 5:07 AM EST - 4 weeks ago

GSK announces $2.2 billion deal, targeting once-per-three-month food allergy drug

Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology

Jan 20, 2026, 2:55 AM EST - 4 weeks ago

Alteogen Announces Exclusive License Agreement with Tesaro, a Subsidiary of GSK, for the Development of a Subcutaneous Formulation of Dostarlimab Enabled by Hybrozyme™ Technology

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

Jan 20, 2026, 2:48 AM EST - 4 weeks ago

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

GSK to buy RAPT Therapeutics for $2.2 billion

Jan 20, 2026, 2:11 AM EST - 4 weeks ago

GSK to buy RAPT Therapeutics for $2.2 billion

RAPT

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Jan 16, 2026, 8:40 AM EST - 5 weeks ago

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

CVS MRK

GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 2:46 PM EST - 5 weeks ago

GSK plc (GSK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

GSK Still Has Room To Run Despite Vaccine Cyclicality

Jan 12, 2026, 9:00 AM EST - 6 weeks ago

GSK Still Has Room To Run Despite Vaccine Cyclicality

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

Jan 12, 2026, 6:15 AM EST - 6 weeks ago

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

SMMT

AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty

Jan 8, 2026, 7:09 PM EST - 6 weeks ago

AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty

ANAB

GSK Licenses Noetik's AI Foundation Models in Anchor Partnership to Transform Cancer Therapeutic Research and Development

Jan 8, 2026, 9:00 AM EST - 6 weeks ago

GSK Licenses Noetik's AI Foundation Models in Anchor Partnership to Transform Cancer Therapeutic Research and Development

GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies

Jan 7, 2026, 11:48 AM EST - 6 weeks ago

GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies

IONS

GSK's chronic hepatitis B treatment meets main goal in key studies

Jan 7, 2026, 2:09 AM EST - 6 weeks ago

GSK's chronic hepatitis B treatment meets main goal in key studies

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

Dec 31, 2025, 6:08 AM EST - 7 weeks ago

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

LLY NVS PFE SNY

Samsung Biologics to buy U.S. drug production facility from GSK for $280 mln

Dec 21, 2025, 5:56 PM EST - 2 months ago

Samsung Biologics to buy U.S. drug production facility from GSK for $280 mln

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Dec 21, 2025, 5:43 PM EST - 2 months ago

Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

Dec 19, 2025, 4:09 PM EST - 2 months ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

BMY MRK AMGN GILD NVS SNY

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

Dec 19, 2025, 3:14 PM EST - 2 months ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

AMGN BMY GILD MRK NVS SNY

Nine of the largest pharma companies ink deals with Trump to lower drug prices

Dec 19, 2025, 2:34 PM EST - 2 months ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

AMGN BMY GILD MRK NVS SNY

GSK: 2026 Looks Good

Dec 18, 2025, 4:25 PM EST - 2 months ago

GSK: 2026 Looks Good

Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma

Dec 16, 2025, 9:55 PM EST - 2 months ago

Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma

US FDA approves GSK's twice-yearly asthma drug

Dec 16, 2025, 6:10 PM EST - 2 months ago

US FDA approves GSK's twice-yearly asthma drug

UK approves GSK's twice-yearly asthma drug

Dec 15, 2025, 12:02 PM EST - 2 months ago

UK approves GSK's twice-yearly asthma drug

Dividend Income: Lanny's October 2025 Summary

Dec 15, 2025, 3:29 AM EST - 2 months ago

Dividend Income: Lanny's October 2025 Summary

BNL BNS BRT CAH CM CSCO DEO

GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade)

Dec 12, 2025, 4:42 PM EST - 2 months ago

GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade)

GSK gets EU regulator backing for expanded use of RSV vaccine

Dec 12, 2025, 9:02 AM EST - 2 months ago

GSK gets EU regulator backing for expanded use of RSV vaccine

European health regulator recommends approval for GSK's twice yearly asthma drug

Dec 12, 2025, 8:58 AM EST - 2 months ago

European health regulator recommends approval for GSK's twice yearly asthma drug

US FDA approves GSK's oral treatment for gonorrhea

Dec 11, 2025, 12:35 PM EST - 2 months ago

US FDA approves GSK's oral treatment for gonorrhea

Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer

Dec 10, 2025, 2:00 AM EST - 2 months ago

Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer

Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns

Dec 5, 2025, 1:35 PM EST - 2 months ago

Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns

MRK SNY

BREAKING: Trump strikes major deal with UK on drug pricing

Dec 1, 2025, 10:15 AM EST - 3 months ago

BREAKING: Trump strikes major deal with UK on drug pricing

AZN EWU EWUS FKU FLGB FXB

AnaptysBio shares tumble after legal fight with GSK over cancer drug license

Nov 21, 2025, 8:52 AM EST - 3 months ago

AnaptysBio shares tumble after legal fight with GSK over cancer drug license

ANAB

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

Nov 21, 2025, 8:48 AM EST - 3 months ago

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

ANAB

GSK, AnaptysBio Sue Each Other Over Cancer Drug License

Nov 21, 2025, 6:14 AM EST - 3 months ago

GSK, AnaptysBio Sue Each Other Over Cancer Drug License

ANAB

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

Nov 21, 2025, 3:50 AM EST - 3 months ago

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

ANAB

GSK plc (GSK) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 19, 2025, 11:23 AM EST - 3 months ago

GSK plc (GSK) Presents at Jefferies London Healthcare Conference 2025 Transcript

Global drugmakers rush to boost US presence as tariff threat looms

Nov 18, 2025, 8:25 AM EST - 3 months ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GILD JNJ LLY

prismmarketview
prismmarketview Feb. 23 at 7:53 PM
Bora Pharmaceuticals (OTCQX: $BORAY) is getting a visibility boost after renewing a five-year, 250 million‑dollar global manufacturing deal with GSK (NYSE: $GSK), locking in long-term CDMO revenue tied to key HIV and malaria medicines. https://prismmarketview.com/bora-pharmaceuticals-secures-250-million-manufacturing-deal-with-gsk-expanding-long-term-revenue-visibility/
0 · Reply
TinyTiger19
TinyTiger19 Feb. 17 at 6:14 PM
$GSK $RELX $LRCX $RDDT ^<>+
0 · Reply
BreakoutPika
BreakoutPika Feb. 17 at 5:51 PM
$CNH $GSK $STZ $NBIX s
0 · Reply
RunnerSignals
RunnerSignals Feb. 17 at 5:30 PM
$ZIM $KW $PGEN $GSK $CNP 5 Stocks Hitting 52-Week Highs Today. volumes are surging well above average, RSI signals extended trends. Watch for follow-through or short-term pullbacks
0 · Reply
Justrise07
Justrise07 Feb. 17 at 4:27 PM
$OCUL tecover your loss with $CAMP 3x buyout coming $GSK
0 · Reply
_EmproX
_EmproX Feb. 17 at 3:17 PM
$APH $GSK $ADBE $RDDT •1
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 17 at 2:56 PM
$GSK
0 · Reply
briefingcom
briefingcom Feb. 17 at 1:27 PM
$GSK: GlaxoSmithKline (+3.4%)receives EU approval for Exdensur in severe asthma and CRSwNP https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260217050658GSK&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
0 · Reply
SanKish
SanKish Feb. 14 at 12:32 AM
$BMY I think this can go much higher based on price action. All tech sell off money is helping pharma too as $PFE , $GSK are doing well too. Which one amongst the 3 will you bet on more?
0 · Reply
inspector_gadget86
inspector_gadget86 Feb. 12 at 3:06 PM
$GSK Cases climb to 933 in South Carolina measles outbreak $OKYO $SPY $DJIA
0 · Reply
NasdaqKnight
NasdaqKnight Feb. 11 at 8:20 AM
UK AI Smart Portfolio – Feb 2026 Update 🇬🇧 AI-driven picks are live and ready to track: If this is helpful to you, tap @NasdaqKnight Healthcare: $GSK, $AZN — global pharma leaders innovating at scale. Tech/Digital: $KNOS , — riding the software & digital transformation wave. Industrials: $AHT, — boosting infrastructure & industrial exposure. Consumer/Brands: $GAW, $DOCS, — premium retail & lifestyle growth. 📊 Why it matters: Built on AI analytics, designed for long-term alpha, beating traditional benchmarks month after month. 💡 Hot take: This mix balances defensive healthcare with high-growth tech & consumer plays — perfect for UK-focused investors seeking diversification with an AI edge. Trending, data-backed, and ready to move — follow momentum and monitor updates.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 10 at 4:08 AM
$GSK RSI: 87.37, MACD: 2.4460 Vol: 3.92, MA20: 51.84, MA50: 50.06 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
1Knevrenuff
1Knevrenuff Feb. 9 at 4:50 PM
$GSK Tough day
0 · Reply
PanicFlip33
PanicFlip33 Feb. 8 at 10:09 AM
$GSK pipeline execution supports long-term growth, while near-term earnings remain defensive.
0 · Reply
calemay
calemay Feb. 6 at 9:40 PM
$GSK Glad I bought 5 years ago
0 · Reply
1Knevrenuff
1Knevrenuff Feb. 6 at 6:52 PM
$GSK 😎
0 · Reply
ZacksResearch
ZacksResearch Feb. 6 at 6:42 PM
Big regulatory win for $GSK — and it’s in a massive disease market 👀 The company just secured EU approval for Nucala as an add-on maintenance treatment for chronic obstructive pulmonary disease in adults, expanding its use beyond prior indications. See what this expanded approval could mean for GSK 👉 https://www.zacks.com/stock/news/2837291/gsk-gets-eu-approval-for-expanded-use-of-nucala-in-copd?cid=sm-stocktwits-2-2837291-teaser-32459&ADID=SYND_STOCKTWITS_TWEET_2_2837291_TEASER_32459
0 · Reply
ZacksResearch
ZacksResearch Feb. 6 at 5:42 PM
$GSK's Nucala gets EU nod for COPD treatment! 🫁✨ With a 57.5% price performance surge in 6 months, GSK's Nucala now approved for COPD in the EU, backed by solid phase III results reducing exacerbations. The drug's unique IL-5 targeting mechanism sets it apart. Discover what this means for GSK's growth 👉 https://www.zacks.com/stock/news/2837291/gsk-gets-eu-approval-for-expanded-use-of-nucala-in-copd?cid=sm-stocktwits-2-2837291-body-32458&ADID=SYND_STOCKTWITS_TWEET_2_2837291_BODY_32458
0 · Reply
1Knevrenuff
1Knevrenuff Feb. 5 at 11:33 PM
$GSK Trump rx
0 · Reply
RunnerSignals
RunnerSignals Feb. 5 at 8:13 PM
52-Week High Fever $JNJ $GSK $KO $GILD $ADI all tagging fresh 52-week highs
0 · Reply
zbrae
zbrae Feb. 5 at 8:02 PM
$SPY 7pm is on pharmas... Trumprx.gov launches at that time $LLY $GSK
1 · Reply
REDBEAR
REDBEAR Feb. 5 at 4:34 PM
$GSK yes!
1 · Reply